Targets › RSVB
1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease; next expected readout Jul 2028.
Open in Phaseline: the race on RSVB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sanofi | Bivalent RSV+HMPV protein vaccine (RPF08203) Respiratory syncytial virus and human metapneumovirus protein vaccine | RSVA, RSVB, HMPV | Phase 2 | Respiratory Syncytial Virus | Jul 2028 |
Respiratory Syncytial Virus (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.